Basilea Pharmaceutica AG Stock Xetra
Stocks
PK5
CH0011432447
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 643M 796M 698M 602M 1.13B 75.09B 1.15B 7.73B 2.99B 37.11B 2.99B 2.92B 129B | P/E 2026 * |
13.8x | P/E 2027 * | 18.1x |
|---|---|---|---|---|---|
| Enterprise Value | 491M 608M 533M 460M 862M 57.32B 880M 5.9B 2.28B 28.33B 2.28B 2.23B 98.23B | EV / Sales 2026 * |
1.87x | EV / Sales 2027 * | 1.61x |
| Free-Float |
91.73% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Basilea Pharmaceutica AG
| Manager | Title | Age | Since |
|---|---|---|---|
David Veitch
CEO | Chief Executive Officer | 61 | 2018-04-18 |
Adesh Kaul
DFI | Director of Finance/CFO | 52 | 2019-04-09 |
Gerrit Hauck
CTO | Chief Tech/Sci/R&D Officer | 62 | 2018-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Thomas Werner
BRD | Director/Board Member | 70 | 2011-11-28 |
| Chairman | 71 | 2013-04-08 | |
Nicole Onetto
BRD | Director/Board Member | 72 | 2017-04-26 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 796M | |
| -0.48% | +7.20% | -5.65% | +1.02% | 46.2B | |
| +2.19% | +11.71% | +393.31% | +580.42% | 38.71B | |
| +2.53% | +13.93% | +21.38% | -12.81% | 31.9B | |
| +1.65% | +3.61% | +16.04% | +55.62% | 31.12B | |
| -4.16% | -2.58% | +8.94% | +25.31% | 23.77B | |
| -0.32% | +12.96% | - | - | 16.2B | |
| +1.37% | +14.53% | +69.64% | +130.07% | 15.05B | |
| +1.00% | +10.30% | +13.31% | +20.31% | 13.74B | |
| +3.63% | +9.53% | +103.97% | +98.73% | 13.42B | |
| Average | +0.74% | +9.14% | +77.62% | +112.33% | 25.57B | |
| Weighted average by Cap. | +0.75% | +8.71% | +88.75% | +130.90% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 263M 325M 285M 246M 462M 30.69B 471M 3.16B 1.22B 15.17B 1.22B 1.19B 52.59B | 267M 331M 290M 250M 470M 31.22B 479M 3.21B 1.24B 15.43B 1.24B 1.22B 53.5B |
| Net income | 51.57M 63.81M 55.94M 48.28M 90.53M 6.02B 92.41M 620M 240M 2.97B 240M 234M 10.31B | 39.24M 48.55M 42.57M 36.74M 68.89M 4.58B 70.32M 472M 182M 2.26B 182M 178M 7.85B |
| Net Debt | -152M -188M -165M -143M -267M -17.77B -273M -1.83B -708M -8.78B -707M -692M -30.46B | -213M -263M -231M -199M -373M -24.81B -381M -2.56B -989M -12.26B -988M -966M -42.52B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
